Capital Impact Advisors, LLC Seagen Inc. Transaction History

Capital Impact Advisors, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$117.37 - $139.17 $7,629 - $9,046	65 Added 2.81%	2,380 $305,000
Q3 2022 Nov 21, 2022	SELL	$135.27 - $180.11 $64,388 - $85,732	-476 Reduced 17.05%	2,315 $317,000
Q2 2022 Aug 15, 2022	SELL	$108.81 - $179.33 $165,717 - $273,119	-1,523 Reduced 35.3%	2,791 $494,000
Q1 2022 May 16, 2022	SELL	$119.61 - $157.85 $1.36 Million - $1.79 Million	-11,361 Reduced 72.48%	4,314 $621,000
Q4 2021 Feb 14, 2022	BUY	$142.57 - $190.86 $2.23 Million - $2.99 Million	15,675 New	15,675 $2.42 Million

Q1 2021 May 18, 2021	SELL	$137.51 - $190.8 $3.81 Million - $5.28 Million	-27,679 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$164.63 - $211.93 $4.56 Million - $5.87 Million	27,679 New	27,679 $4.85 Million

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Capital Impact Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Capital Impact Advisors, LLC with notifications on news.